Metraipolis › archive › dc_fa723b26e6bf

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase… — Europe PMC PMID:42498834

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42498834
DOI
10.1038/s41375-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-10-06T07:52:36.220Z
SHA-256 of the archived text
fa2247b35780201e15cda3db050626dbfe0be4336619840d5f85c93e7cff904c
Stable URL of this page
https://metraipolis.com/documento/dc_fa723b26e6bf

How to cite

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase… — Europe PMC PMID:42498834 — Europe PMC (en), https://europepmc.org/article/MED/42498834 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa723b26e6bf (Metraipolis archive dc_fa723b26e6bf, sha256 fa2247b35780201e15cda3db050626dbfe0be4336619840d5f85c93e7cff904c)
BibTeX
@misc{dcfa723b26e6bf,
  title = {Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase… — Europe PMC PMID:42498834},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42498834},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa723b26e6bf; sha256 fa2247b35780201e15cda3db050626dbfe0be4336619840d5f85c93e7cff904c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42498834. Agents can read the archived copy with the MCP tool read_document.